Jiangsu Hengrui Pharmaceuticals Co., Ltd. (A shares) (HENGRUI) income statement

SHH · Healthcare · Drug Manufacturers - Specialty & Generic · 20,602 employees · CEO Sun Piaoyang

Price: CN¥48.97 +1.05%
Market cap: CN¥312B
Enterprise value: CN¥269B
Last report: Q3 '26 filed 2026-09-30
Next report: 2027-04-19 EPS est. CN¥0.32

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (A shares) (HENGRUI) reported revenue of CN¥8.95B for Q3 '26 (+20.6% year on year), operating income of CN¥2.81B (31.3% of revenue) and net income of CN¥2.46B. Over the last four quarters revenue was CN¥32.9B.

Income statement

Income statement	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26	Q3 '26
Revenue	CN¥5.81B	CN¥6B	CN¥7.6B	CN¥6.59B	CN¥7.8B	CN¥7.21B	CN¥8.56B	CN¥7.43B	CN¥8.44B	CN¥8.14B	CN¥7.32B	CN¥8.95B
Cost of revenue	CN¥905M	CN¥943M	CN¥915M	CN¥976M	CN¥1.05B	CN¥1.07B	CN¥1.05B	CN¥1.08B	CN¥1.26B	CN¥1.09B	CN¥1.16B	CN¥1.11B
Gross profit	CN¥4.9B	CN¥5.05B	CN¥6.69B	CN¥5.61B	CN¥6.75B	CN¥6.14B	CN¥7.51B	CN¥6.35B	CN¥7.18B	CN¥7.05B	CN¥6.16B	CN¥7.84B
Research & development	CN¥1.23B	CN¥1.22B	CN¥1.82B	CN¥1.51B	CN¥2.03B	CN¥1.53B	CN¥1.69B	CN¥1.72B	CN¥1.95B	CN¥1.65B	CN¥1.75B	CN¥1.93B
Sales & marketing	-CN¥367M	CN¥1.76B	CN¥794M	CN¥3.55B	-CN¥554M	CN¥1.97B	CN¥715M	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0
General & administrative	-CN¥248M	CN¥576M	CN¥231M	CN¥1.07B	-CN¥209M	CN¥586M	CN¥389M	CN¥3.26B	CN¥2.98B	CN¥2.82B	CN¥0	CN¥0
Other operating expenses	CN¥3.32B	-CN¥142M	CN¥1.5B	-CN¥1.88B	CN¥3.33B	-CN¥28M	CN¥1.64B	CN¥80.9M	CN¥136M	CN¥78.8M	CN¥80.4M	CN¥166M
Operating expenses	CN¥3.93B	CN¥3.42B	CN¥4.34B	CN¥4.25B	CN¥4.6B	CN¥4.05B	CN¥4.44B	CN¥5.06B	CN¥5.06B	CN¥4.55B	CN¥4.56B	CN¥5.04B
Operating income	CN¥969M	CN¥1.64B	CN¥2.35B	CN¥1.36B	CN¥2.15B	CN¥2.09B	CN¥3.07B	CN¥1.28B	CN¥2.11B	CN¥2.5B	CN¥1.6B	CN¥2.81B
Interest income	CN¥126M	CN¥166M	CN¥222M	CN¥120M	CN¥115M	CN¥77.1M	CN¥179M	CN¥242M	CN¥291M	CN¥320M	CN¥391M	CN¥332M
Interest expense	CN¥1.16M	CN¥17.8M	CN¥3.31M	CN¥39.2M	CN¥2.25M	CN¥10.9M	CN¥739K	CN¥690K	CN¥2M	CN¥448K	CN¥2.55M	CN¥1M
Other non-operating income (gains on investments, FX ...)	CN¥418M	CN¥158M	CN¥335M	-CN¥56.4M	CN¥578M	CN¥60.3M	CN¥328M	-CN¥90.8M	-CN¥184M	-CN¥61.5M	CN¥0	CN¥0
Total non-operating income	-CN¥114M	-CN¥133M	-CN¥99.7M	-CN¥25.4M	-CN¥62.4M	-CN¥10.4M	-CN¥97.6M	CN¥76.1M	CN¥182M	CN¥61M	CN¥798M	-CN¥28.9M
Income before tax	CN¥855M	CN¥1.5B	CN¥2.25B	CN¥1.34B	CN¥2.08B	CN¥2.08B	CN¥2.98B	CN¥1.36B	CN¥2.3B	CN¥2.56B	CN¥2.4B	CN¥2.78B
Income tax	CN¥27.9M	CN¥135M	CN¥188M	CN¥147M	CN¥362M	CN¥199M	CN¥397M	CN¥55.5M	CN¥339M	CN¥276M	CN¥211M	CN¥318M
Net income	CN¥829M	CN¥1.37B	CN¥2.06B	CN¥1.19B	CN¥1.72B	CN¥1.87B	CN¥2.58B	CN¥1.3B	CN¥1.96B	CN¥2.28B	CN¥2.18B	CN¥2.46B
EPS (basic)	CN¥0.13	CN¥0.21	CN¥0.32	CN¥0.19	CN¥0.27	CN¥0.30	CN¥0.40	CN¥0.20	CN¥0.30	CN¥0.35	CN¥0.33	CN¥0.37
EPS (diluted)	CN¥0.13	CN¥0.21	CN¥0.32	CN¥0.19	CN¥0.27	CN¥0.30	CN¥0.40	CN¥0.20	CN¥0.29	CN¥0.35	CN¥0.33	CN¥0.37
Shares (basic, weighted)	6.35B	6.52B	6.35B	6.35B	6.34B	6.25B	6.36B	6.6B	6.62B	6.6B	6.6B	6.6B
Shares (diluted, weighted)	6.35B	6.52B	6.35B	6.35B	6.34B	6.25B	6.36B	6.6B	6.65B	6.6B	6.6B	6.6B
Depreciation & amortization	CN¥222M	CN¥212M	CN¥212M	CN¥223M	CN¥223M	CN¥231M	CN¥231M	CN¥240M	CN¥240M	CN¥0	CN¥268M	CN¥0
EBITDA	CN¥773M	CN¥1.69B	CN¥2.23B	CN¥1.64B	CN¥1.79B	CN¥2.26B	CN¥2.98B	CN¥1.62B	CN¥2.54B	CN¥2.56B	CN¥1.87B	CN¥2.81B

Income statement	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	CN¥11.1B	CN¥13.8B	CN¥17.4B	CN¥23.3B	CN¥27.7B	CN¥25.9B	CN¥21.3B	CN¥22.8B	CN¥28B	CN¥31.4B
Cost of revenue	CN¥1.43B	CN¥1.85B	CN¥2.34B	CN¥2.92B	CN¥3.36B	CN¥3.76B	CN¥3.5B	CN¥3.56B	CN¥3.88B	CN¥4.76B
Gross profit	CN¥9.66B	CN¥12B	CN¥15.1B	CN¥20.4B	CN¥24.4B	CN¥22.1B	CN¥17.8B	CN¥19.3B	CN¥24.1B	CN¥26.7B
Research & development	CN¥1.18B	CN¥1.76B	CN¥2.67B	CN¥3.9B	CN¥4.99B	CN¥5.94B	CN¥4.89B	CN¥4.95B	CN¥6.58B	CN¥6.67B
Sales & marketing	CN¥4.35B	CN¥5.19B	CN¥6.46B	CN¥8.52B	CN¥9.8B	CN¥9.38B	CN¥7.35B	CN¥7.58B	CN¥8.34B	CN¥0
General & administrative	CN¥2.27B	CN¥1.19B	CN¥1.63B	CN¥2.24B	CN¥3.07B	CN¥2.86B	CN¥2.31B	CN¥2.42B	CN¥2.56B	CN¥11.8B
Other operating expenses	-CN¥1.16B	CN¥21.2M	-CN¥300M	-CN¥460M	-CN¥496M	-CN¥698M	-CN¥907M	-CN¥585M	-CN¥833M	CN¥152M
Operating expenses	CN¥6.64B	CN¥8.18B	CN¥10.5B	CN¥14.2B	CN¥17.4B	CN¥17.5B	CN¥13.7B	CN¥14.3B	CN¥16.6B	CN¥18.7B
Operating income	CN¥3.02B	CN¥3.81B	CN¥4.6B	CN¥6.15B	CN¥7.01B	CN¥4.66B	CN¥4.11B	CN¥4.91B	CN¥7.49B	CN¥8.02B
Interest income	CN¥126M	CN¥87.4M	CN¥70.1M	CN¥127M	CN¥290M	CN¥588M	CN¥385M	CN¥477M	CN¥603M	CN¥810M
Interest expense	CN¥1.87M	CN¥36.6M	CN¥4.78M	CN¥6.88M	CN¥5.49M	CN¥4.71M	CN¥6.49M	CN¥6.66M	CN¥5.56M	CN¥15.1M
Other non-operating income (gains on investments, FX ...)	CN¥179M	CN¥232M	CN¥537M	CN¥648M	CN¥735M	CN¥900M	CN¥1.05B	CN¥734M	CN¥1.01B	-CN¥704M
Total non-operating income	-CN¥9.87M	-CN¥48.6M	-CN¥97.6M	-CN¥93.9M	-CN¥112M	-CN¥199M	-CN¥143M	-CN¥243M	-CN¥321M	CN¥689M
Income before tax	CN¥3.01B	CN¥3.76B	CN¥4.5B	CN¥6.06B	CN¥6.9B	CN¥4.47B	CN¥3.97B	CN¥4.67B	CN¥7.17B	CN¥8.71B
Income tax	CN¥379M	CN¥466M	CN¥438M	CN¥729M	CN¥587M	-CN¥17.7M	CN¥153M	CN¥389M	CN¥833M	CN¥991M
Net income	CN¥2.59B	CN¥3.22B	CN¥4.07B	CN¥5.33B	CN¥6.33B	CN¥4.53B	CN¥3.91B	CN¥4.3B	CN¥6.34B	CN¥7.71B
EPS (basic)	CN¥0.41	CN¥0.50	CN¥0.64	CN¥0.84	CN¥1.00	CN¥0.71	CN¥0.61	CN¥0.68	CN¥1.00	CN¥1.19
EPS (diluted)	CN¥0.41	CN¥0.50	CN¥0.63	CN¥0.84	CN¥1.00	CN¥0.71	CN¥0.61	CN¥0.68	CN¥1.00	CN¥1.18
Shares (basic, weighted)	6.32B	6.29B	6.36B	6.34B	6.36B	6.38B	6.37B	6.33B	6.34B	6.5B
Shares (diluted, weighted)	6.32B	6.39B	6.43B	6.34B	6.36B	6.38B	6.37B	6.33B	6.34B	6.51B
Depreciation & amortization	CN¥255M	CN¥320M	CN¥381M	CN¥646M	CN¥448M	CN¥541M	CN¥644M	CN¥794M	CN¥871M	CN¥942M
EBITDA	CN¥3.1B	CN¥3.9B	CN¥4.44B	CN¥6.15B	CN¥6.72B	CN¥4.31B	CN¥3.7B	CN¥4.97B	CN¥7.35B	CN¥9.67B

Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in CNY.

Revenue, operating income and growth

quarterly

Margins

quarterly

Costs as % of revenue

quarterly

The other statements

Balance sheetCash, investments, assets, debt, liabilities and equityOpen Cash flowOperating cash flow, capex, free cash flow, buybacks and dividendsOpen

Sources

Statements, segment revenue, metrics and estimates: Financial Modeling Prep.

Data as of 2026-11-02